Pharmacokinetics of nisoldipine in renal dysfunction.
The pharmacokinetics of nisoldipine have been studied after oral administration of one 10 mg tablet to 3 groups of patients: Group A (n = 8) with a mean creatinine of 90 ml/min, Group B (n = 8) with a mean creatinine clearance of 12 ml/min and Group C of 12 patients on maintenance haemodialysis. All of them were studied off-dialysis and 7 were also studied on a dialysis day. No significant differences were observed between Groups A, B and C (on an interdialysis day) in AUC (0-7h), tmax, Cmax and plasma protein binding. Unchanged nisoldipine could not be recovered from the urine in any patient. Haemodialysis did not significantly affect AUC, tmax and Cmax, and nisoldipine could not be detected in the dialysate. The results indicate that the dose of nisoldipine need not be changed in patients with renal dysfunction, and that a supplementary dose is not required after haemodialysis. Blood pressure in the uraemics fell more than in the patients with good renal function.
Boelaert
J
J
Algemeen Ziekenhuis St. Jan, Brugge, Belgium.
Valcke
Y
Y
Dammekens
H
H
De Vriese
G
G
Ahr
G
G
Schurgers
M
M
Daneels
R
R
Bogaert
M G
MG
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D015737:Nisoldipine; D006435:Renal Dialysis
D002121:Calcium Channel Blockers; D015737:Nisoldipine; D009543:Nifedipine